Pharmaron's UK subsidiary invests $30m in healthcare fund

Pharmaron Beijing (SZSE:300759) announced that its wholly-owned UK subsidiary, Pharmaron UK Limited, will commit USD 30 million as a limited partner in BLC Healthcare USD Fund I L.P. The investment aims to capitalize on specialized investment capabilities within the biopharmaceutical industry. The fund, with a target size of USD 100 million, will focus on global investments in the biotech and healthcare sectors, targeting early and growth-stage projects for long-term capital appreciation. The general partner of the fund is BLC Investment Management (Cayman) Company Limited, and the special limited partner is BLC SLP (BVI) Limited. Pharmaron UK's contribution represents 85.71% of the currently committed capital of USD 3.5 million. The investment is subject to standard investment risks and will be accounted for according to accounting standards.